ArcticZymes Technologies ASA (OSL:AZT)
kr 13.4 -0.06 (-0.45%) Market Cap: 684.36 Mil Enterprise Value: 451.17 Mil PE Ratio: 167.50 PB Ratio: 2.15 GF Score: 69/100

Q2 2020 Arcticzymes Technologies ASA Earnings Call Transcript

Aug 19, 2020 / 06:30AM GMT
Release Date Price: kr57 (+17.28%)
Jethro Holter
ArcticZymes Technologies ASA - CEO

Okay. So I'm going to kick off now. So welcome to the Q2 presentation. Since this is a virtual meeting, we have muted everybody's microphones, and we will unmute those at the end for the Q&A session. So today, it's myself, Jethro Holter, CEO; and Børge Sørvoll, our CFO, will walk you through the presentation today.

Today actually marks a new era for us. It's the first time we actually present as ArcticZymes Technologies. We rebranded the company from Biotec Pharmacon to ArcticZymes Technologies back in June. We are very proud of the new brand. It fits seamlessly and resonates well with our commitment to the enzyme business being our core future focus moving forward.

So with the new brand, we have a clear mission and vision. So our vision is, with our daily work, we want to make an important contribution to a healthier world. Driven by this goal, our experienced scientists are constantly working to find and unlock new solutions. What this essentially means is at the end of the day, for us, it's more of enzymes. We want to improve

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot